Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Healthcare Sector Verification

This section contains information intended for healthcare professionals.

Please confirm that you are affiliated with a healthcare organization.

HbA1c – The Hidden Factors Biological interferences

This webinar is presented in English.

Published: 7/14/2021 | Modified: 10/20/2026

Abstract

The presentation comprises of a brief introduction regarding the effects of excessive alcohol consumption, its impact globally and the timely apparition of serum CDT.

Serum total CDT was an improvement over traditional markers but had its pitfalls and limitations, until its path towards standardisation through the IFCC CDT Working group manifested and its evolution to CDT-IFCC.

Upon its recognition to being a very specific marker for chronic excessive alcohol consumption, CDT-IFCC is a valuable marker in both clinical (for example, primary care, psychiatry, lifestyle drinking, antenatal first trimester and emergency departments) and forensic settings (for example, driver licensing, aviation, locomotion, and maritime).

Capillary electrophoresis is the commercial alternative separation technique, which aims to mirror the IFCC approved standard reference HPLC procedure.

There is a great need to raise awareness and educate the importance of CDT-IFCC which is currently the only IFCC approved alcohol marker compared to other upcoming markers and they tend to be associated with short term drinking. CDT-IFCC has a half life of approximately two weeks and makes it an excellent retrospective marker.

The high specificity of CDT-IFCC in the assessment of chronic excessive consumption over traditional markers, its successful standardisation, its uses in both clinical and forensic settings can only indicate that it is ‘time for change’, with inclusive use of the marker by diagnostic service centres and increasing requests by their clients. Collaboration by diagnostic laboratories, local authorities, psychiatrists, primary cares, and CDT manufacturers would be a good approach to promote demand and uptake for CDT-IFCC.

What will you learn?

  • Red Blood Cell Age: The Hidden Determinant of HbA1c

    Learn how red blood cell lifespan influences HbA1c independently of glucose levels, helping explain why patients with similar HbA1c values can have very different average glucose concentrations.

  • Clinical Factors That Can Distort HbA1c Results

    Explore how conditions such as pregnancy, iron deficiency, G6PD deficiency, and other hematologic changes affect HbA1c interpretation through their impact on red blood cell turnover.

  • Hemoglobin Variants and Accurate Diabetes Monitoring

    Understand the importance of detecting hemoglobin variants and selecting appropriate HbA1c methods to avoid analytical and clinical misinterpretation in diabetes management.

Hemoglobin A1c has become such an important component of management of diabetes
Dr. David B. Sacks

About David B. Sacks

David B. Sacks, MB, ChB, FRCP (UK), FRCPath, is Senior Investigator and Chief of the Clinical Chemistry Service at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, USA. An internationally recognized expert in diabetes diagnostics and laboratory medicine, Dr. Sacks has made significant contributions to the standardization and clinical application of hemoglobin A1c (HbA1c) testing. He has authored numerous peer-reviewed publications and has played a leading role in developing guidelines for diabetes diagnosis and monitoring.

Dr. Sacks is Chair Emeritus of the National Glycohemoglobin Standardization Program (NGSP) Steering Committee and has been instrumental in advancing the accuracy and harmonization of HbA1c measurements worldwide. His research focuses on diabetes biomarkers, analytical quality in laboratory testing, and the impact of hemoglobin variants on HbA1c interpretation. As a respected educator and speaker, he continues to shape best practices in clinical chemistry and diabetes care globally.

David B. Sacks

About John Higgins

John Higgins, MD, is Associate Professor of Systems Biology at Harvard Medical School and Associate Pathologist at Massachusetts General Hospital. His research focuses on applying quantitative and systems biology approaches to improve the understanding and interpretation of clinical laboratory tests. Dr. Higgins is internationally recognized for his work on red blood cell physiology, hemoglobin A1c (HbA1c) measurement, and the impact of red blood cell lifespan on diabetes monitoring.

Through a combination of mathematical modeling, clinical investigation, and laboratory medicine, Dr. Higgins has advanced understanding of the biological factors that influence HbA1c beyond glycemia alone. His work has helped highlight the role of red blood cell age in HbA1c variability and its potential implications for more personalized assessment of glycemic control. As a pathologist, researcher, and educator, he is dedicated to improving the accuracy and clinical utility of diagnostic testing.

John Higgins

Test associated with this resource

Deepen your expertise with additional webinars

This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.

HbA1c – The Hidden Factors Biological interferences